B of A Securities maintains Buy on Bristol-Myers Squibb

0 min read | Published on 06 Jul 2026, 08:42 PM |Updated on 11 Jul 2026, 02:37 AM

Reviewed by

Radhika SScanX News Team

Key Highlights

B of A Securities analyst Tim Anderson maintained a Buy rating on Bristol-Myers Squibb but lowered the price target to $66 from $67. Cantor Fitzgerald analyst Carter Gould reaffirmed a Neutral rating with a price target of $54.

*this image is generated using AI for illustrative purposes only.

B of A Securities analyst Tim Anderson has maintained a Buy rating on Bristol-Myers Squibb, while lowering the price target from $67 to $66. The adjustment reflects the firm's updated valuation perspective on the pharmaceutical company's stock performance.

Separately, Cantor Fitzgerald analyst Carter Gould has reaffirmed a Neutral rating on Bristol-Myers Squibb, maintaining a price target of $54. This rating reiteration suggests that Cantor Fitzgerald sees limited immediate upside or downside risk at the current valuation levels.

Analyst	Rating	Price Target
Tim Anderson (B of A Securities)	Buy	$66
Carter Gould (Cantor Fitzgerald)	Neutral	$54

Bristol-Myers Squibb continues to be monitored for its operational and financial developments.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

What operational developments might drive B of A Securities' more optimistic valuation compared to Cantor Fitzgerald?

How could upcoming clinical trial results influence the divergence in analyst price targets?

What impact might patent expirations for key drugs have on Bristol-Myers Squibb's future revenue?

Bristol Myers Squibb to announce Q2 2026 results on July 30

0 min read | Published on 18 Jun 2026, 05:19 PM |Updated on 18 Jun 2026, 05:19 PM

Reviewed by

Shriram SScanX News Team

Add as a preferred
source on Google

Key Highlights

Bristol Myers Squibb is set to release its Q2 2026 financial results on July 30, 2026, followed by an executive conference call at 8:15 a.m. ET. The company will provide live webcast access via its Investor Relations website, with a replay available shortly after the event.

*this image is generated using AI for illustrative purposes only.

Bristol Myers Squibb will announce its financial results for the second quarter of 2026 on July 30, 2026. Company executives will review the financial performance with the investment community during a conference call scheduled to begin at 8:15 a.m. ET. Investors and the general public are invited to listen to a live audio webcast of the proceedings.

Materials related to the conference call will be accessible on the company's Investor Relations website prior to the start of the event. A replay of the webcast will be available approximately three hours after the conclusion of the call.

Key Event Details

Event	Date	Time
Q2 2026 Results Announcement	July 30, 2026	8:15 a.m. ET
Live Webcast Access	July 30, 2026	8:15 a.m. ET
Webcast Replay Availability	July 30, 2026	~3 hours post-call

Bristol Myers Squibb focuses on discovering, developing, and delivering innovative medicines for patients with serious diseases. Further information regarding the company and its financial updates can be found on its official website.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

What key performance indicators will investors focus on during the Q2 2026 earnings call?

How might Bristol Myers Squibb's pipeline developments influence its financial outlook for the remainder of 2026?

What impact could macroeconomic conditions have on the company's revenue projections?